ROSE Zur Rose Group AG

New stock exchange ticker symbol for DocMorris: DOCM (formerly ROSE)

DocMorris AG / Key word(s): Strategic Company Decision/Miscellaneous
New stock exchange ticker symbol for DocMorris: DOCM (formerly ROSE)

11.05.2023 / 07:00 CET/CEST

Frauenfeld, 11 May 2023
 

Press release

 

New stock exchange ticker symbol for DocMorris: DOCM (formerly ROSE)

As of today, the ticker symbol for the shares of DocMorris AG – formerly Zur Rose Group AG – traded on the SIX Swiss Exchange is now "DOCM". ISIN and Valor remain unchanged.

The Annual General Meeting approved the change of name from Zur Rose Group AG to DocMorris AG on 4 May 2023.

 

 

Investors and analyst contact
Dr. Daniel Grigat, Group Head of Investor Relations & Sustainability
Email: , phone: 9

Media contact
Lisa Lüthi, Group Director Communications
Email: , phone: +41 52 724 08 14

 

Agenda

17 August 2023 2023 Half-Year Results (11 a.m. CEST: Conference Call/Webcast)
19 October 2023 Q3/2023 Trading Update

 

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, marketplace and professional healthcare with strong brands in Germany and other European countries. As Germany's largest online pharmacy, it operates DocMorris, the best-known health platform. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands, with a capacity of over 27 million parcels per year. In Spain and France, the company operates the leading marketplace for health and personal care products in Southern Europe. With its business model, DocMorris offers its patients, customers and partners a broad range of products and services. In doing so, DocMorris is pursuing its vision of creating a digital health ecosystem for everyone to manage their health in one click. The company was renamed from Zur Rose Group AG to DocMorris AG in May 2023 after the Swiss business was sold to Migros/Medbase. Excluding the Swiss business, about 2,200 employees in Germany, the Netherlands, Spain, France and Switzerland generated an external revenue of CHF 1,159 million serving around 10 million active customers in 2022. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

 


End of Media Release
Language: English
Company: DocMorris AG
Walzmühlestrasse 49
8500 Frauenfeld
Switzerland
Phone: 4
ISIN: CH0042615283
Listed: SIX Swiss Exchange
EQS News ID: 1629693

 
End of News EQS News Service

1629693  11.05.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1629693&application_name=news&site_id=research_pool
EN
11/05/2023

Underlying

ROSEZur Rose Group AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zur Rose Group AG

 PRESS RELEASE
Free
ROSE Zur Rose Group ...

DocMorris grows 6.7 per cent in 2024 and accelerates Rx growth in the ...

DocMorris AG / Key word(s): Development of Sales DocMorris grows 6.7 per cent in 2024 and accelerates Rx growth in the fourth quarter 21.01.2025 / 06:58 CET/CEST Frauenfeld, 21 January 2025 Press release DocMorris grows 6.7 per cent in 2024 and accelerates Rx growth in the fourth quarter All business divisions contribute to revenue growth in 2024 OTC revenues increase by 6.7 per cent in 2024 New Rx customers grew fivefold and Rx revenue up 16.6 per cent in the fourth quarter of 2024 TeleClinic with profitable doubling of revenue in 2024 Cash position of CHF 95 million...

January 21, 2025 1 EN
 PRESS RELEASE
Free
ROSE Zur Rose Group ...

DocMorris wächst 6.7 Prozent in 2024 und beschleunigt Rx-Wachstum im v...

DocMorris AG / Schlagwort(e): Umsatzentwicklung DocMorris wächst 6.7 Prozent in 2024 und beschleunigt Rx-Wachstum im vierten Quartal 21.01.2025 / 06:58 CET/CEST Frauenfeld, 21. Januar 2025 Medienmitteilung DocMorris wächst 6.7 Prozent in 2024 und beschleunigt Rx-Wachstum im vierten Quartal Alle Geschäftsbereiche tragen zum Umsatzwachstum 2024 bei OTC-Umsatz 2024 erhöht sich um 6.7 Prozent Rx-Neukunden verfünffacht und Rx-Umsatz plus 16.6 Prozent im vierten Quartal 2024 TeleClinic mit profitabler Umsatzverdoppelung in 2024 Cashbestand von CHF 95 Mio. per Ende 2024 DocM...

January 21, 2025 1 DE
 PRESS RELEASE
Free
ROSE Zur Rose Group ...

DocMorris beschleunigt Rx-Wachstum

DocMorris AG / Schlagwort(e): Quartals-/Zwischenmitteilung DocMorris beschleunigt Rx-Wachstum 15.10.2024 / 06:58 CET/CEST Frauenfeld, 15. Oktober 2024 Medienmitteilung DocMorris beschleunigt Rx-Wachstum Rx-Umsatzwachstum von 12.2 Prozent im dritten Quartal Beschleunigung auf über 25 Prozent in den letzten Wochen Starke Zunahme der Rx-Neukunden OTC-Wachstum von 1.9 Prozent Pablo Ros Gomez wird neuer CTO Schliessung des Logistikstandorts in Halle (DE) Das E-Rezept-Geschäft von DocMorris nimmt weiter Fahrt auf: Im dritten Quartal 2024 wuchs der Aussenumsatz mit versch...

October 15, 2024 1 DE
 PRESS RELEASE
Free
ROSE Zur Rose Group ...

DocMorris accelerates Rx growth

DocMorris AG / Key word(s): Quarterly / Interim Statement DocMorris accelerates Rx growth 15.10.2024 / 06:58 CET/CEST Frauenfeld, 15 October 2024 Press release DocMorris accelerates Rx growth Rx revenue growth of 12.2 per cent in the third quarter Acceleration to over 25 per cent in the last few weeks Strong increase in new Rx customers OTC growth of 1.9 per cent Pablo Ros Gomez becomes new CTO Closure of the logistics site in Halle (DE) DocMorris' e-prescription business continues to gain momentum: In the third quarter of 2024, external revenue of prescription med...

October 15, 2024 1 EN
 PRESS RELEASE
Free
ROSE Zur Rose Group ...

DocMorris mit beschleunigtem und signifikantem eRx-Wachstum bei Neukun...

DocMorris AG / Schlagwort(e): Quartals-/Zwischenmitteilung DocMorris mit beschleunigtem und signifikantem eRx-Wachstum bei Neukunden, Marktanteil und Umsatz 11.07.2024 / 06:58 CET/CEST Frauenfeld, 11. Juli 2024 Medienmitteilung DocMorris mit beschleunigtem und signifikantem eRx-Wachstum bei Neukunden, Marktanteil und Umsatz Verdreifachung der Rx-Neukundenzahl seit CardLink-Einführung Verdoppelung und kontinuierliche Steigerung des eRx-Marktanteils seit Januar 2024 17 Prozent Umsatzwachstum rezeptpflichtiger Medikamente (Rx) gegenüber Vorquartal Seit Mitte April ist de...

July 11, 2024 1 DE

ResearchPool Subscriptions

Get the most out of your insights

Get in touch